In recent years, the prevalence of asthma is increasing in both adults and children (2) . Asthma is a complex genetic trait caused by environmental factors in genetically predisposed individuals (1) . It is reported that atopic asthma is a hereditary disease because it develops from the infancy (3).
There are some reports that the development of allergic disease such as 4 4 asthma, atopic dermatitis, and atopic conjunctivitis during the adolescent period is reduced in the children from the mother sensitized with allergens before or during pregnancy and lactation (4) (5) (6) (7) (8) (9) . Transportation of Th-2 cell (7), IFN-γ (8) or antigen specific IgG from mother to offspring reduce the development of allergic diseases. Especially, the transportation of maternal antigen specific IgG via amniotic fluid, placenta and breast milk plays an important role in the passive immunity (7) (8) (9) . The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from mother to her fetus. Therefore FcRn that expresses on placenta, intestinal epithelia, liver, lung, and vascular endothelium plays the important role in the transportation of maternal IgG (10).
FcRn binds to the Fc domain of IgG at acidic pH (pH < 6.0) but not at a physiological pH (pH > 7.0) (11) and functions in the bidirectional transport of IgG across polarized epithelia (12) and a related cell biologic process that is associated with the protection of monomeric IgG from degradation (13). FcRn also regulates mucosal immune responses to luminal bacteria and pathogenesis of colitis(14,15).
First, we confirmed that the development of the allergic airway inflammation is reduced in the FcRn-dependent manner by sensitizing mother mice before pregnancy and inducing allergy. Next, we evaluated the 5 5 effect of the antigen specific IgG in the breast milk whether it can reduce the development of allergic airway inflammation of offspring. Offspring were sensitized and challenged with ovalbumin.
Materials and Methods

Animals
Six-to eight-week-old female C57BL/6 mice (WT; specific pathogen free, Nippon CLEA, Tokyo, Japan) and FcRn 
Agents
The following drugs and chemicals were purchased commercially: ovalbumin (OVA; Sigma-Aldrich Japan, Tokyo, Japan). Mouse OVA specific IgG1 was kindly gifted from H.Karasuyama (Department of Immune Regulation, Tokyo Medical and Dental University Graduate with intraperitoneal injections of 50g of OVA with 1mg of alum twice or three times. Then, they were exposed to 1% (wt/vol) OVA diluted in sterile phosphate-buffered saline (PBS) for 30 min on 3 consecutive days.
Collection of bronchoalveolar lavage fluid
Twenty-four hours after last exposure, bronchoalveolar lavage (BAL) was performed by instilling and aspirating two 0.8-ml aliquots of PBS (recovery >85%). Cells in the lavage fluid were counted by using a hemocytometer. BAL fluid was centrifuged at 1500 g for 5 min (at 4°C).
Lung histology
Mouse lungs were intratracheally instilled with 10% buffered formalin at a pressure of 20cmH 2 O for 24h and then embedded in paraffin. They were stained with hematoxylin and eosin or with periodic acid-Schiff.
Collection of blood 7 Blood was collected from heart via the anterior mediastinum. Blood was centrifuged at 3000 g for 10 min (at 4°C), and supernatants were stored at -20°C.
Immunoglobulin assay
Mouse OVA-specific IgG1 serum levels were measured by using a MOUSE IgG1 ELISA KIT (BETHYL). Mouse OVA-specific IgE serum levels were measured by using a DS Mouse IgE ELISA (DS Pharma Biomedical Co.,Ltd.)
Statistical analysis
Results are expressed as means ± SE. Statistical significance between groups was assessed by Mann Whitney test. The p values for significance were set at 0.05. In order to examine the role of maternal antigen specific IgG1 injection into mothers, OVA-specific IgG1 (1mg / body) was injected intravenously into wild-type or FcRn +/-mother, immediately after birth (day 1). Offspring were sensitized with OVA and alum on day 28 and 35. Serum OVA-specific IgE levels were analyzed by ELISA on day 42, and challenged with nebulized OVA on day 43-45 respectively. Airway inflammation were assessed by cell counts of BALF on day 46 ( Figure 3A) . By intravenous administration of OVA-specific IgG1 to mother, OVA-specific IgE level was significantly reduced in wild-type offspring, but not in FcRn -/-offspring (WT offspring from treated mother, 1.590 ± 1.171 ng / ml; FcRn -/-offspring, 75.66 ± 14.60 ng / ml; WT offspring from naïve mother, 58.65 ± 10.44 ng / ml; p < 0.01; Figure 3B ). The cell counts of BALF were also significantly reduced in wild-type offspring from treated mother, but Previous studies showed that the transportation of IFN-γ (8) or Th-2 cell (7) with OVA specific IgG is necessary for maternal passive immunity. Our study showed that maternal OVA specific IgG1 in breast milk transported 16 16 via FcRn in the epithelial-cell layer of intestine alone can prevent the development of allergic airway inflammation of OVA during young days.
Conclusion
In this study, we confirmed that the immune therapy before or during pregnancy and lactating period is beneficial to reduce the development of allergic disease during young days. It is necessary to pay attention to antigen exposure and immune therapy before conception, during pregnancy or breast feeding period in order to prevent allergy. 
